Skip to main content

Coronavirus (COVID-19) Updates: Visitation Policies (New! 11.25.20) | How We're Keeping You Safe | Latest COVID Information

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
menu
URMC / Research / Clinical Trials / Study Details

UMMY18121 / Amgen Deno Smol Lipe IIT / Brea Lipe

Research Question:
Is denosumab, delivered as an injection under the skin, safe and well-tolerated in people with smoldering multiple myeloma? And can denosumab reduce the risk of getting multiple myeloma?

Basic Study Information

Purpose:
This study will assess the safety and tolerability of denosumab in smoldering multiple myeloma subjects as well to see if denosumab can reduce subjects' risk of getting multiple myeloma.

Location: University of Rochester Medical Center
Study Reference #: UMMY18121

Lead Researcher (Principal Investigator)

Lead Researcher:  Brea Lipe

Study Contact Information

Study Coordinator: Jessica Mackowiak
Email: jessica_ellis@urmc.rochester.edu

Additional Study Details

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search